Comment 1: Comment on the National Institute for Clinical Excellence Technology Appraisal Guidance on the use of donepezil, rivastigmine and galantamine for the treatment of Alzheimer's disease
NHS Quality Improvement Scotland
Record ID 32003000775
English
Details
Project Status:
Completed
URL for project:
http://www.nhshealthquality.org/
Year Published:
2001
URL for published report:
n/a
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Scotland, United Kingdom
MeSH Terms
- Cholinesterase Inhibitors
- Neuroprotective Agents
- Donepezil
- Rivastigmine
- Galantamine
- Alzheimer Disease
Contact
Organisation Name:
Health Technology Board for Scotland
Contact Address:
Delta House, 50 West Nile Street Glasgow G1 2NP Scotland United Kingdom Tel: +44 141 225 6988; Fax: +44 141 221 3262
Contact Name:
shtg.hcis@nhs.net
Contact Email:
shtg.hcis@nhs.net
Copyright:
Health Technology Board for Scotland (HTBS) (merged into NHS Quality Improvement Scotland (NHS QIS))
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.